vaccination-1215279_960_720

BioNTech’s melanoma vaccine shows promise in early interim analysis

pharmafile | July 30, 2020 | News story | Research and Development |  BioNTech, Cancer, pharma 

While the company has more recently drawn headlines for its COVID-19 efforts, BioNTech has unveiled promising interim Phase 1 data for its mRNA-based cancer vaccine BNT111, the most advanced  of the company’s five FixVac candidates, in patients with stage 3 B-C and stage 4 melanoma.

Through analysis of repeated intravenous doses ranging from 7.2µg to 400µg, the company said that the therapy “mediates durable objective responses” both as a monotherapy and in combination with PD-1 checkpoint blockade.

The trial examined the therapy’s efficacy in a subset of 42 checkpoint-inhibitor (CPI)-experienced melanoma patients assessed by imaging of metastatic lesions before and after vaccination. BioNTech said that vaccination “resulted in the expansion and activation of circulating tumour-antigen-specific T cells with memory-function that exhibited strong cytotoxic activity against tumour cells.” 

These T cells were also shown to exhibit a Th1 phenotype, and, with continuous monthly vaccination, persisted for over a year.

Advertisement

At the time of analysis, three of the 25 patients receiving BNT111 alone saw a partial response, seven saw their disease stabilise, and one patient achieved complete metabolic remission of metastatic lesions. Furthermore, six of the 17 patients receiving BNT111 in combination with anti-PD-1 achieved a partial response.

The company said that the candidate was well tolerated with no dose limiting toxicity. It is currently also progressing FixVac candidates through Phase 1 studies in prostate, ovarian and triple negative breast cancer, as well as HPV16-positive cancers.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content